4.7 Article

MBNL2 Regulates DNA Damage Response via Stabilizing p21

期刊

出版社

MDPI
DOI: 10.3390/ijms22020783

关键词

MBNL2; RNA-binding protein; p21; DNA damage response; Chk1; cancer

资金

  1. National Natural Science Foundation of China [31571418]
  2. Shenzhen Science and Technology Innovation Commission [JCYJ20170817161908969]

向作者/读者索取更多资源

RNA-binding protein MBNL2 plays a crucial role in regulating tumor cell proliferation and DNA damage response by modulating the PI3K/AKT pathway and affecting the expression of p21. Depletion of MBNL2 leads to increased phosphorylation levels of Chk1 and influences DNA damage response, ultimately altering tumor cell fate by inhibiting DNA damage repair and promoting DNA damage-induced apoptosis.
RNA-binding proteins are frequently dysregulated in human cancer and able to modulate tumor cell proliferation as well as tumor metastasis through post-transcriptional regulation on target genes. Abnormal DNA damage response and repair mechanism are closely related to genome instability and cell transformation. Here, we explore the function of the RNA-binding protein muscleblind-like splicing regulator 2 (MBNL2) on tumor cell proliferation and DNA damage response. Transcriptome and gene expression analysis show that the PI3K/AKT pathway is enriched in MBNL2-depleted cells, and the expression of cyclin-dependent kinase inhibitor 1A (p21(CDKN1A)) is significantly affected after MBNL2 depletion. MBNL2 modulates the mRNA and protein levels of p21, which is independent of its canonical transcription factor p53. Moreover, depletion of MBNL2 increases the phosphorylation levels of checkpoint kinase 1 (Chk1) serine 345 (S345) and DNA damage response, and the effect of MBNL2 on DNA damage response is p21-dependent. MBNL2 would further alter tumor cell fate after DNA damage, MBNL2 knockdown inhibiting DNA damage repair and DNA damage-induced senescence, but promoting DNA damage-induced apoptosis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据